Modelling the lifetime economic consequences of glaucoma in France

Journal of Medical Economics

Volumn 12, Issue 1, 2009, Pages 9-16

  Nordmann, Jean Philippe ^a   Lafuma, Antoine ^b   Berdeaux, Gilles ^c,d  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b CEMKA EVAL   (France)

^c University of Paris Cité   (France)

^d Alcon France   (France)

Author keywords

Economics; Glaucoma; Life long treatment; Model

Indexed keywords

ADULT; AGED; ARTICLE; COST CONTROL; ECONOMIC ASPECT; EYE SURGERY; FRANCE; GLAUCOMA; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTRAOCULAR HYPOTENSION; LIFESPAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MEDICAL CARE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PATIENT CARE; PROBABILITY; PUBLIC HEALTH; SENSITIVITY ANALYSIS; SOCIAL ASPECT;

BLINDNESS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; FRANCE; GLAUCOMA; HEALTH CARE COSTS; HUMANS; LONG-TERM CARE; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS;

EID: 67649600720     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990902728729     Document Type: Article

References (69)

1. Goldstein H. Magnitude and causes of blindness: sources and limitations of data. In: Freemann JS. Editor. Clinical Ophthalmology, Vol 5 (52). Philadelphia: Lippincott, 1990: 1-10.
2. Kitazawa Y, Horie T, Aoki S. Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977;95:1180-1189.
3. Nizankowska MH, Kaczmarek R. Prevalence of glaucoma in the Wroclaw population. The Wroclaw Epidemiological Study. Ophthalmic Epidemiol 2005;12(6):363-371.
4. Anton A, Andrada MT, Mujica V et al. Prevalence of primary open-angle glaucoma in a Spanish population: the Segovia study. J Glaucoma 2004;13(5):371-376.
5. de Voogd S, Ikram MK, Wolfs RC et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112(9):1487-1493.
6. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology 2002;109(6):1047-1051.
7. Ekstrom C. Prevalence of open-angle glaucoma in central Sweden. The Tierp glaucoma survey. Acta Ophthalmol Scand 1996;74:107-112.
8. Kahn HA, Leibowitz HM, Ganley JP et al. The Framingham eye study. I. Outline and major prevalence findings. II. Associations of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 1977;106:33-41.
9. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38(1):83-91.
10. Topouzis F, Wilson MR, Harris A et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol 2007;144(4):511-519.
11. Friedman DS, Jampel HD, Muñoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol 2006;124(11):1625-1630.
12. Armaly MF. Ocular pressure and visual fields: a ten-year follow-up study. Arch Ophthalmol 1969;81:25-44.
13. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003;44(9):3783-3789.
14. Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 2001;108(11):1966-1972.
15. Dietelsman I, Vingerling JR, Algra D et al. Primary open-angle glaucoma, intraocular pressure and systemic blood pressure in the general elderly population. Ophthalmology 1995;102:54-60.
16. Dietelsman I, De Jong PTV, Stolk R et al. Primary open-angle glaucoma, intraocular pressure and diabetes mellitus in the general elderly population. Ophthalmology 1996;103(8):1271-1275.
17. Tielsch JM, Katz J, Quigley HA et al. Family history and risk of primary open-angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994;112:69-73.
18. Martin MJ, Sommer A, Gold EB et al. Race and primary open-angle glaucoma. Am J Ophthalmol 1985;58:529-535.
19. Hattenhauer MG, Johnson DH, Ing HH et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105(11):2099-2104.
20. Ramrattan RS, Wolfs RC, Panda-Jonas S et al. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. Arch Ophthalmol 2001;119(12):1788-1794.
21. Wilson M, Kosoko O, Cowan C et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002;134(3):399.
22. Kwon YH, Kim CS, Zimmerman MB et al. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol 2001;132(1):47-56.
23. Katz J. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Ophthalmology 1999;106(2):391-395.
24. Hiller R, Podgor MJ, Sperduto RD et al. High intraocular pressure and survival: the Framingham Studies. Am J Ophthalmol 1999;128(4):440-445.
25. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701-713.
26. The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130(4):429-440.
27. Anderson DR. The management of elevated intraocular pressure with normal optic discs and visual fields. Surv Ophthalmol 1977;21:479-489.
28. Fingeret M. Glaucoma medications, glaucoma therapy, and the evolving paradigm. J Am Optom Assoc 1998;69(2):115-121.
29. Reyes E, Izquierdo NJ, Blasini M. Adverse drugs reactions associated with glaucoma medications. Bol Asoc Med P R 1997;89(4-6):51-55.
30. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004;13(4):283-290.
31. Oostenbrink JB, Rutten-van Mölken MP, Opdenoordt TS et al. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in The Netherlands. J Glaucoma 2001;10(3):184-191.
32. Oostenbrink JB, Rutten-van Mölken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999;98(3):285-99.
33. Kobelt G, Jonsson L, Gerdtham U et al. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236(11):811-821.
34. Jonsson B, Krieglstein G. Primary open-angle glaucoma. Differences in International Treatment Patterns and Costs. Oxford: Isis Medical Media, 1999.
35. Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 2001;79(3):286-288.
36. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998;7(2):95-104.
37. Kobelt G, Jönsson L. Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care 1999;15(1):207-219.
38. Roulland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management. A review. Drug Aging 2005;22(4):315-321.
39. Baudouin C, Rouland JF, Le Pen C. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. Eur J Ophthalmol 2003;13(Suppl 4):S53-60.
40. Weinstein MC. The costs of prevention. J Gen Intern Med 1990;5(5 Suppl):S89-92.
41. Hjelmgren J, Berggren F, Andersson D. Health economics guidelines - similarities, differences and some implications. Value Health 2001;4:225-250.
42. Nordmann JP, Lafuma A, Pradet S et al. Clinical outcomes of glaucoma treatments over a patient life: a Markov model. J Glaucoma 2005;14(6):463-469.
43. Denis P, Lafuma A, Berdeaux G. Medical outcome of glaucoma therapy from a nationwide representative survey. Clin Drug Investig 2004;24(6):343-352.
44. Kymes S. Clinical outcomes of glaucoma treatment over a patient lifetime: a Markov model (letter). J Glaucoma 2006;15(5):471-472; author reply 472-473.
45. European Medicines Agency. Available at: http://www.emea.europa.eu/.
46. Morniche P. L'enquête HID de l'INSEE - Objectifs et schéma organisationnel. Courrier des Statistiques 1997;87,88,7-18.
47. Ravaud J-F, Letourmy A, Ville I. Identifying the population with disability: the approach of an INSEE survey on daily life and health. Population-E 2002;57(3):529-552.
48. OECD - Organisation for Economic Co-operation and Development. OECD health data: a comparative analysis of 29 Countries. Credes, 1999; Eco-Santé software, Paris.
49. Brown MM, Brown GC, Sharma S et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-331.
50. Sharma S, Brown GC, Brown MM et al. Converting visual acuity to utilities. Can J Ophthalmol 2000;35:267-272.
51. Lafuma A, Brézin A, Lopatriello S et al. Evaluation of non-medical costs associated with visual impairment in four European countries (France, Italy, Germany and the United Kingdom). PharmacoEconomics 2006;24(2):193-205.
52. Auquier P, Auray JP, Berdeaux G et al. French guidelines for the economic evaluation of health care technologies. Methodological recommendations. Work carried out by the Members of the Collège des Économistes de la Santé (the French Health Economists Association) under the coordination of émile Lévy and Gérard de Pouvourville. CES, Collège des économistes de la Santé, Paris, September 2004: 1-86. Available at : http://www.ces-asso.org.
53. Etablissements de soins de longue durée pour personnes âgées, Infos DGAS, n°70, Ministére de la Santé, 2000 Paris.
54. Morniche P. L'enquête HID de l'INSEE - Objectifs et schéma organisationnel. Courrier des Statistiques 1998;87,88. Paris: INSEE.
55. Brézin A, Lafuma A, Fagnani F et al. Prevalence and burden of self-reported blindness and low vision for subjects living in institutions: a nation-wide survey. Health Qual Life Outcomes 2005;3(1):27.
56. Brézin A, Lafuma A, Fagnani F et al. Prevalence and burden of blindness, low vision and visual impairment in institution: a nation-wide survey. Arch Ophthalmol 2005;123(8):1117-1124.
57. Brézin A, Lafuma A, Fagnani F et al. Blindness, low vision and other handicaps as risk factors of institution. Br J Ophthalmol 2004,88(10):1330-1337.
58. Evans RL. Loneliness, depression and social activity after determination of legal blindness. Psychol Rep 1983;52:603-608.
59. Scott IU, Schein OD, Feuer WJ et al. Emotional distress in patients with retinal disease. Am J Ophthalmol 2001;131(5):548-589.
60. Legood R, Scuffham P, Cryer C. Are we blind to injuries in the visually impaired? A review of the literature. Inj Prev 2002;8(2):155-160.
61. Cacciatore F, Abete P, Maggi S et al. Disability and 6-year mortality in elderly population. Role of visual impairment. Aging Clin Exp Res 2004;16:382-388.
62. Taylor HR, McCarty CA, Nanjan MB. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc 2000;98:91-96.
63. Krumpaszky HG, Dietz K, Mickler A et al. Mortality in blind subjects. A population-based study on social security files from Baden-Württemberg. Ophthalmologica 1999;213:48-53.
64. Thompson JR, Gibson JM, Jagger C. The association between visual impairment and mortality in elderly people. Age Ageing 1989;18:83-88.
65. Wang JJ, Mitchell P, Simpson JM et al. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001;119:1186-1190.
66. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004;88(9):1107-1112.
67. Donati G. Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in agerelated macular degeneration in routine clinical practice in Switzerland. J Fr Ophtalmol 2007;30(8):837-41 [French].
68. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resourc Alloc 2008;6:12.
69. Karnon J, Czoski-Murray C, Smith K et al. A preliminary model based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technol Assess 2008;12(27):iii-iv, ix-124.